Exercise During Chemotherapy Treatment As Adjuvant Program in Patients with Lymphoma: EDONOLA Study.

In this study, the effectiveness of an individualized adjuvant exercise program will be analyzed in a homogeneous population of people diagnosed with lymphoma in active treatment. Taking into account the limited scientific evidence that currently exists in people affected by lymphoma and active treatment, the study could be of great relevance when it comes to providing scientific evidence in this very little field studied. The study will try to respond to the evident need to focus the research area on supervised exercise in people with lymphoma in a way innovative, with the aim of generating new hypotheses that overcome existing limitations and facilitate the introduction of this type of interventions into the health system. The present study will also analyze the effect of exercise from a gender perspective, an aspect not systematically studied until now, providing a new vision on the baseline differences and after intervention of a program based on of sex.

The study will include adults with lymphoma with special focus on the subanalysis of the group of patients equal or more than 70 years old. The lymphoma unit of the Donostia University Hospital (HUD) is part of the Onkofrail project that analyzes the impact of a physical activity in older cancer patients. The Onkofrail study has included everything type of solid tumors and very diverse treatments, which is a limitation methodology that could condition the analysis of the results. Therefore, the need of proposing a new exercise project in a homogeneous population such as that of people with lymphoma, the most prevalent hemopathy in our environment, which has a great survival, but present important adverse effects secondary to treatment systemic. 30 people with lymphoma and treatment have been included in the Onkofrail study asset. The preliminary results of said pilot study have been used for the design of this new study, making adaptations, both in the recruitment time, as well as inclusion and exclusion criteria, which guarantee and optimize the correct research development.

Main objective:

The main objective is to assess whether a supervised (2 days/week) combined (resistance+aerobic interval training) exercise intervention, plus 2 days/week unsupervised for 20 weeks improves cardiorespiratory fitness (CRF) in people diagnosed with lymphoma undergoing chemotherapy, compared to a control group receiving only general recommendations.

Secondary objectives:

1. To estimate cardiorespiratory capacity (VO2peak) through a field test Modified Shuttle Walking Test (MSWT) and other covariates related to body composition, heart rate, among others. Validation of the predictive model. 2. To characterise and define the profile of the population diagnosed with lymphoma at the physical, emotional, and biochemical (biomarker) and immune system level prior to an intervention with exercise. 3. To investigate whether the implementation of an exercise programme adjuvant to immunochemotherapy treatment modifies fatigue, adherence (actual dose-intensity), and toxicity related to clinical treatment. 4. To analyse whether the intervention with exercise is effective in increasing strength levels, improving quality of life and sleep. 5. To clarify whether there are sex differences in the efficacy of the exercise programme adjuvant to immunochemotherapy treatment. 6. To analyse the benefit of adding exercise programmes in different subgroups of people with lymphoma, with a special focus on the group of patients aged ≥70 years, with the aim of maximising the cost-effectiveness of implementation in the care routine in all patients. 7. To analyse the degree of adherence to the programme: degree of attendance at planned sessions and percentage of participants who complete the post-intervention evaluation. 8. To report the degree of satisfaction by people affected by lymphoma, as reported in an interview.

• Sociodemographic, etiological and clinical health variables (A) [Срок оценки: 20 weeks]
• Sociodemographic, etiological and clinical health variables (B) [Срок оценки: 20 weeks]
• Sociodemographic, etiological and clinical health variables (C) [Срок оценки: 20 weeks]
• Sociodemographic, etiological and clinical health variables (D) [Срок оценки: 20 weeks]
• Sociodemographic, etiological and clinical health variables (E) [Срок оценки: 20 weeks]
• Sociodemographic, etiological and clinical health variables (F) [Срок оценки: 20 weeks]
• Functionality and fragility variables at times T0, T1 and T2 (A.1.) [Срок оценки: 20 weeks]
• Functionality and fragility variables at times T0, T1 and T2 (A.2.) [Срок оценки: 20 weeks]
• Functionality and fragility variables at times T0, T1 and T2 (B.1.) [Срок оценки: 20 weeks]
• Functionality and fragility variables at times T0, T1 and T2 (B.2.) [Срок оценки: 20 weeks]
• Functionality and fragility variables at times T0, T1 and T2 (C) [Срок оценки: 20 weeks]
• Functionality and fragility variables at times T0, T1 and T2 (D) [Срок оценки: 20 weeks]